Trial Profile
A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Gilteritinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms LACEWING
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 08 Mar 2024 This trial has been completed in France, according to European Clinical Trials Database record.
- 28 Jun 2023 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
- 15 Mar 2023 Planned primary completion date changed from 31 Jan 2023 to 31 Dec 2023.